QIAGEN N.V.

QIAGEN N.V. is a global leader in molecular diagnostics, sample technologies, genomics, and life science research solutions. Founded in 1984 and headquartered in Venlo, Netherlands, the company develops innovative technologies that enable researchers and healthcare professionals to isolate, analyze, and interpret DNA, RNA, and proteins for disease diagnosis, precision medicine, and scientific discovery.

QIAGEN’s product portfolio includes molecular diagnostic assays, PCR technologies, next-generation sequencing (NGS) sample preparation, bioinformatics software, companion diagnostics, infectious disease testing, oncology diagnostics, forensic applications, and laboratory automation systems. Its technologies are widely used in hospitals, clinical laboratories, academic research institutions, pharmaceutical companies, and public health organizations worldwide.

The company invests heavily in molecular biology, digital PCR, automation, artificial intelligence, and genomic data analysis to support personalized healthcare and precision diagnostics. QIAGEN maintains manufacturing and research facilities across Europe, North America, and Asia while complying with international regulatory requirements established by the US FDA, European IVDR, ISO, and other health authorities.

By combining scientific innovation with high-quality molecular technologies, QIAGEN has become one of the world’s most respected companies in molecular diagnostics and life sciences, supporting healthcare professionals in improving disease detection, treatment selection, and patient outcomes globally.